OxThera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary hyperoxaluria (PH), announces the randomization of the first patient into its phase III study, EPHEX, with Oxabact.

Study OC5-DB-02 (EPHEX) is a randomized, placebo-controlled, 52-week study with the goal to investigate the efficacy and safety of Oxabact in patients with PH. The purpose of the study is to show that Oxabact can halt or delay the disease progression and preserve kidney function.

“This is an important step for OxThera in developing a promising treatment approach for patients suffering from Primary hyperoxaluria, a devastating disease with high unmet medical need. With Oxabact, we are attempting to reduce the systemic oxalate crystal burden and hope to demonstrate that chronic treatment with Oxabact can preserve kidney function for these patients.” said Matthew Gantz, CEO of OxThera.